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Abstract
Sleep disordered breathing (SDB) is a common co-morbidity in patients with heart failure 
(HF). Both its forms — central and obstructive sleep apnea — are highly prevalent in this 
population. SDB fragments sleep, impairs life quality, worsens exercise tolerance, worsens HF 
and is an independent predictor of poor prognosis. Still, SDB remains largely undiagnosed. 
Therefore, early detection of SDB seems to be of primary importance, especially in the presen-
ce of new diagnostic and therapeutic methods. Treatment with continuous positive airway 
pressure (CPAP) increases left ventricular ejection fraction and stroke volume in virtually all 
HF patients with obstructive and in 50% with central sleep apnea. For those in whom central 
sleep apnea is not suppressed by CPAP, a trial of adaptive servoventilation is recommended. 
Although no randomized, controlled trials have shown improvement in mortality, several obser-
vational studies have shown that effective treatment of both forms of sleep apnea with various 
positive airway pressure devices improves survival of HF patients. Currently, 2 large trials with 
newer masked based therapies with adaptive servoventilation are in progress. This article is 
a brief overview of present knowledge, the pathophysiology, diagnostic approach and therapy of 
SDB. (Cardiol J 2013; 20, 4: 345–355)
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Introduction
Sleep disordered breathing (SDB) is one of the 
most common and yet largely under-diagnosed co-
-morbidity in patients with heart failure (HF) [1, 2]. 
It leads to further deterioration of cardiac function 
and worsens prognosis [3–6]. SDB may be a po-
tential therapeutic target as its effective treatment 
improves quality of life, exercise tolerance and, 
possibly, long term prognosis [5–10]. However, 
the importance of SDB remains unrecognized and 
the disorder itself is diagnosed rarely and remains 
untreated [5]. The availability of simple screening 
methods and severe clinical consequences of SDB 
justify routine and widespread screening and appro-
priate treatment. 
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Diagnosis and defi nitions
Overnight polysomnography (PSG) is the gold 
standard for diagnosing SDB. These studies are 
completed in a sleep laboratory with monitoring. 
During a sleep study, breathing disorders can be 
detected and differentiated into central (CSA) and 
obstructive sleep apnea (OSA), based on presence 
of respiratory effort. Multiple parameters are moni-
tored including oro-nasal airfl ow, thoracoabdominal 
movements, arterial blood oxyhemoglobin satura-
tion, electrocardiogram (ECG), at least 2 channel 
electroencephalogram (EEG), chin and anterior 
tibialis electromyogram (EMG) and electroocu-
logram (EOG). With this montage total recording 
time , total wake time, total sleep time, sleep sta-
ges, apnea/hypopnea index (AHI) and arousal index 
are accurately determined.
Apnea is defi ned as a cessation of respiratory 
airfl ow for 10 s or more. If respiratory effort, mani-
fested by abdominal and/or chest wall movement, is 
present, OSA is diagnosed (Fig. 1). CSA is diagno-
sed when no respiratory muscles activity is detec-
ted (Fig. 2). Hypopnea is defi ned as the reduction 
in airfl ow by at least 50% of the preceding baseline 
associated with the drop in arterial blood oxygen 
saturation of at least 3%. An alternative defi nition 
of hypopnea is reduction of airfl ow by at least 30% 
and associated with 4% or more desaturation. The 
number of apnea and hypopnea episodes during 
1 h of sleep, known as AHI, is a valuable tool in 
recognition of sleep disorders and determination 
of their severity. Normally AHI should not exceed 
5/h. An AHI of 5 to < 15/h of sleep is considered 
mild, ≥ 15 to < 30/h moderate and ≥ 30/h severe 
SDB [11]. Disordered breathing events are also 
associated with arousals. The number of arousals 
per hour of sleep is calculated as the arousal index. 
Due to low accessibility and high cost of PSG 
new diagnostic methods have been developed. Self-
-assessment questionnaires, such as the Epworth 
Sleepiness Scale or Berlin Questionnaire, esti-
mating the probability of SDB presence based on 
subjective symptoms are in common use. These 
questionnaires have been successfully used in 
general population, but as noted below they are 
Figure 1. Acute consequences of obstructice sleep apnea (OSA). An example of OSA in a patient with heart failure. 
Note that the apnea is terminated with an arousal seen on brain waves. Also note progressively increasing negative 
intrathoracic pressure swings measured by an esophageal balloon. The thoracoabdominal excursions are out of 
phase during the apnea, but in phase during recovery. Also note desaturation with apnea and reoxygenation with 
resumption of breathing. Modified from: Javaheri S. Cardiovascular disorders. In: Kryger MH ed. Atlas of clinical sleep 
medicine. WB Saunders, Philadelphia 2010.
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Figure 2. Hunter-Cheyne-Stokes breathing in heart failure. An example of periodic breathing in a patient with heart 
failure in N2 (nonrapid-eye-movement sleep). Note crescendo decrescendo changes in tidal breathing which sand-
wich central apneas. Also, note that arousals occur at the peak of hyperventilation. This contrasts with the temporal 
association of arousals occurring at the termination of obstructive apneas (see Figure 2). Modified from: Javaheri S. 
Cardiovascular disorders. In: Kryger MH ed. Atlas of clinical sleep medicine. WB Saunders, Philadelphia 2010.
virtually useless for suspicion of sleep apnea in 
HF patients. 
There are numerous clinical findings that 
may suggest OSA in general population, such 
as snoring, interrupted sleep, increased daytime 
sleepiness, morning headaches, nocturia, chronic 
fatigue, arterial hypertension, and arrhythmias. 
A number of these symptoms such as interrupted 
sleep, nocturia, fatigue and arrhythmias are non-
specifi c, being present in HF itself. Furthermore, 
in patients with HF, the prevalence of excessive 
daytime sleepiness is similar between those with 
or without sleep apnea [12, 13]. For all these afore-
mentioned reasons, sleep apnea remains under 
diagnosed in HF [5]. Snoring, however, remains 
a predictor of OSA in patients with HF as it is, in 
general population. Similarly, hand in hand with 
snoring, obesity remains a major risk factor for 
OSA in HF, and its prevalence is on the rise in 
this population. 
Diagnosis of CSA in patients with HF is most 
problematic as HF patients with CSA are generally 
thin and do not snore much [12]. Major predictors of 
CSA are atrial fi brillation, very low left ventricular 
ejection fraction (LVEF less than 20%), presence of 
nocturnal ventricular arrhythmias and a low steady 
state arterial PCO2 [13]. 
Recently, new methods which seem to be use-
ful in identifying patients with SDB have appeared. 
One of them utilizes heart rate variability (HRV) 
assessment. A typical pattern of HRV with very 
low frequency rhythms has been found in patients 
with HF and SDB, especially with CSA (for review 
see reference [14]). This can be measured at home 
with a Holter monitor, but is not diagnostic for the 
type or severity of SDB. Another method that can 
be applied in patients with implanted pacemakers, 
relies on the assessment of minute ventilation by 
evaluation of changes in transthoracic impendence 
between the pacemaker case and the electrode 
tip. It enables detection of decreased ventilation 
episodes. However, it cannot differentiate between 
obstructive and central episodes. Importantly, this 
method showed high sensitivity in identifying se-
vere SDB when compared to traditional PSG, sug-
gesting its potential application as a screening tool 
in patients with implantable cardiac devices [15].
Home sleep-studies with cardiorespiratory 
polygraphy have been utilized for diagnosis of sleep 
apnea both in general population and in patients 
with HF. A major the difference with in laboratory 
PSG is lack of EEG. There are several portable 
devices available: Embletta, ApneaLink, Stardust, 
Venla, to name a few. Typically, they consist of 
nasal pressure detector, belts detecting thoraco-
-abdominal movement and fi nger pulse oximeter. 
They have some potential advantages over PSG, 
such as lower cost, better sleep quality in home 
environment than in sleep laboratory, portability and 
broad accessibility. However, home sleep-studies 
cannot replace full PSG as for lack of EEG, total 
sleep time cannot be determined. As a result, the 
true AHI (AHI/h of sleep) is underestimated, as the 
denominator used for the calculation is the total 
recording time, and not the hours of sleep. This is 
an important consideration, since patients with HF 
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have curtailed sleep time even after spending 2 con-
secutive nights in sleep laboratory for habituation 
[12, 13]. Therefore, a number of HF patients with 
SDB may go unrecognized as a negative polygraphy 
does not rule out signifi cant sleep apnea.
Epidemiology of SDB in HF
The prevalence of SDB has been extensively 
studied both in patients with reduced as well as 
preserved LVEF. In the population of patients with 
HF and reduced left ventricular ejection fraction, 
SDB occurs frequently. Multiple studies (Table 1) 
show a high prevalence of sleep apnea both central 
and obstructive in this population [13, 16–20]. 
One important difference is the variability in the 
distribution of central vs. obstructive disordered 
breathing events. This diffi culty stems from accu-
rately differentiating obstructive and central sleep 
hypopneas from each other. Combining the results 
of multiple studies from various countries, the ove-
rall prevalence of sleep apnea in patients with HF 
with a threshold of an AHI of 15 or more per hour 
is 52%. Central apnea accounts for 32% and ob-
structive apnea for 20% (Table 1). It is important to 
emphasize that the subjects enrolled in most recent 
studies were consecutive patients with stable HF 
on contemporary therapy. Therefore, the results 
of these studies are consistent with those of early 
studies in which only 10% of the patients were on 
a beta-blocker (Table 1). We therefore conclude 
that introduction of beta-blockers for treatment of 
HF has had no major impact on the prevalence of 
sleep apnea in this population. 
There is growing evidence that sleep apnea 
is also highly prevalent in patients with HF and 
preserved ejection fraction. Bitter et al. [21] used 
echocardiography and right and left heart cathe-
terization to characterize sleep apnea in 244 con-
secutive patients with HF and preserved ejection 
fraction. In this study, 33% had coronary artery 
disease, 44% had systemic hypertension and 23% 
had hypertrophic/restrictive cardiac disease. Using 
polygraphy without EEG, 48% of the patients had 
an AHI ≥ 15 h of recording time. As noted earlier, 
polygraphy may underestimate the severity of 
sleep apnea, therefore the data from patients with 
HF and preserved ejection fraction are virtually 
similar to those in patients with HF and redu-
ced ejection fraction. Twenty-fi ve percent of the 
244 patients had OSA and 23% had CSA. 
Pathomechanisms of SDB
Central sleep apnea
Central sleep apnea occurs in the backgro-
und of a specific respiratory pattern known as 
Hunter-Cheyne-Stokes breathing (HCSB). It 
had first been described by John Hunter [22], 
37 years before it was described by Cheyne in 1818 
[23] (see references [1] and [2] for more details). 
HCSB is characterized by recurrent episodes of 
apnea/hypopnea in the context of long crescendo-
-decrescendo breathing cycles. The length of the 
cycle refl ects the prolonged circulation time, the 
pathologic feature of HF. HCSB occurs in patients 
with HF both during the day and at night, but CSA 
occurs only during sleep or when the patient is 
dozing. Pathological mechanisms underlying CSA 
have been widely investigated within last decade 
and explained in detail in a recent monograph [24]. 
The important factors involved in pathophysiology 
of CSA are: diminished PCO2 reserve (difference 
between eupneic PCO2 and apnea threshold) [24, 
Table 1. Prevalence of sleep apnea (AHI ≥ 15/h), central (CSA) and obstructive (OSA) sleep apnea in re-
cent prospective studies in patients with heart failure with reduced ejection fraction; NA — not available. 
Modified from: [2].
Country [year] Author N AHI ≥ 15/h CSA OSA b-blockers
*USA [2006] Javaheri 100 49% 37% 12% 10%
USA [2008] MacDonald 108 61% 31% 30% 82%
*Canada [2007] Wang 287 47% 21% 26% 80%
*UK [2007] Vazir 55 53% 38% 15% 78%
Germany [2007] Oldenburg 700 52% 33% 19% 85%
*Germany [2009] Hagenah 50 64% 44% 20% 100%
*Germany [2010] Jilek 273 64% 50% 14% 88%
*Portugal [2010] Ferreira 103 46% NA NA 90%
Total 1676 54% 34% 20% 81%
*Asterisk indicates studies using polysomnography.
www.cardiologyjournal.org 349
Magdalena Krawczyk et al., Sleep disordered breathing in patients with heart failure
25], and augmented central and peripheral hypoxic 
and hypercapnic chemosensitivity [26, 27]. These 
will be discussed in details below (Fig. 2).
Hyperventilation is a consequence of chronic 
pulmonary congestion and interstitial pulmonary 
edema. In response to pulmonary congestion va-
gus nerve becomes activated (by non-myelinated 
type C nerve fi bers in parenchyma of the lungs, 
in alveolar bronchioles, alveolar capillaries and 
distention-sensitive receptors), that leads to cen-
tral activation of breathing. Meanwhile, pulmonary 
congestion also decreases the PCO2 reserve and 
predisposes to central apnea [24], this by mecha-
nisms not fully explained. Therefore, during sleep, 
even a slight increase in ventilation caused by 
arousal or changes in position may lead to a drop 
in PCO2 below the apnea threshold and results in 
occurrence of apnea episode. Cessation of bre-
athing leads to accumulation of CO2 which is the 
chemical stimulus for resumption of ventilation. 
Enhanced chemoreceptor sensitivity propagates 
excessive ventilation and subsequent drop in 
PCO2 below apnea threshold and the next apnea 
[1, 2, 24, 26]. The duration of the cycle of periodic 
breathing is proportional to circulation time from 
lung to chemoreceptors.
In HF patients with CSA, PCO2 does not 
increase at sleep onset which narrows PCO2 re-
serve increasing the likelihood of developing CSA. 
It has been suggested [2, 24] that lack of increase 
in PCO2 results from inability to decrease ventila-
tion that normally occurs at sleep onset. Patients 
with HF, particularly those with severely impaired 
diastolic function, may develop an increase in pul-
monary capillary pressure due to increased venous 
return, which in turn refl exively increases respira-
tory rate and ventilation at sleep onset. Therefore, 
nocturnal rostral shift of fl uid into the lung causing 
pulmonary congestion enhances CSA [28]. 
Regarding hypocapnia 2 points are emphasi-
zed. First, in HF awake steady state arterial hypo-
capnia is highly predictive of CSA [29]. How ever, 
in a group of patients with liver cirrhosis and pre-
served ejection fraction (mean EF 60%), despite 
hypocapnia (mean arterial PCO2 = 32 mm Hg), 
central apneas were rarely observed. On the 
other hand hypocapnia in HF subjects with 
impaired ejection fraction (mean EF 23%) was 
associated with increased number of AHI epi-
sodes and central apneas [30]. Thus, it may not 
be hypocapnia itself, but diminished difference 
between eupneic PCO2 and apnea threshold, 
known as PCO2 reserve that predisposes to CSA, 
as discussed earlier [24, 25]. 
Another factor which may increase the li-
kelihood of developing central apnea is cerebro-
vascular response to PCO2 which may result in 
reduced PCO2 reserve. To this end Xie et al. [31] 
used indomethacin to reduce cerebral blood fl ow 
response to PCO2 and using a mechanical ventila-
tor in pressure support mode gradually reduced 
PCO2 until apnea occurred. They observed that in 
conditions of decreased cerebrovascular reactivity, 
PCO2 reserve needed to produce an apnea dropped 
from 6.3 to 4.4 mm Hg [31]. This is an important 
observation as cerebral blood vessels reactivity to 
CO2 is diminished in patients with HF [32], which 
may lead to a signifi cant decrease in PCO2 reserve 
and consequently promote breathing instability.
Obstructive sleep apnea
The pathomechanisms of OSA are complex and 
their detailed description remains beyond the goal 
of this article, however they have been discussed 
in detail elsewhere [33]. The main underlying me-
chanism of OSA is partial or complete occlusion of 
upper airway, mainly due to genioglossus muscle 
relaxation in the face of altered mechanical pro-
perties of the upper airway. With this background, 
negative pressure within airways generated by 
diaphragm contraction during inspiration results 
in pharyngeal collapse and obstruction.
Factors that impair upper airway patency rela-
te to upper airway anatomical abnormalities such as 
micrognathia, retrognathia, hypertrophy of palatine 
tonsils, macroglossia and increased adipose tissue 
deposition. In patients with HF, rostral fl uid shift 
in supine position causing venous congestion and 
upper airway edema may further predispose to 
upper airway collapse [28]. 
We must emphasize however, that most fre-
quently both types of apnea occur together during 
one night. This was recognized early on for which 
reason we used arbitrary criteria to defi ne whether 
the breathing disorder is predominantly central 
or obstructive in nature [12, 13, 34]. Presence of 
a hybrid disordered breathing and the predominant 
form of sleep apnea depends on a number of factors 
such as use of alcohol, medications, changes in 
position and body weight and fl uid shifts. 
Clinical consequences
Normally, about 80% of the sleep period is 
non-rapid eye movement sleep (NREM), when 
increased parasympathetic activity and decreased 
sympathetic activity is observed. This is associa-
ted with a drop in heart rate, cardiac output and 
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blood pressure, therefore, there is cardiovascular 
quiescence. However, in the face of sleep apnea, 
NREM sleep is fragmented with arousals, and 
along with other consequences of sleep apnea, 
a hyperadrenergic state is created [1, 2]. 
We must emphasize that the biological con-
sequences of sleep apnea which adversely affect 
cardiovascular function are qualitatively similar in 
both forms of apnea although such adverse effects 
are more severe in OSA than CSA (Fig. 1).
Consequences of sleep apnea in HF
The SDB events are characterized by cycles of 
apnea/hypopnea followed by recovery. The 3 main 
consequences of SDB are hypoxia/hypercapnia, 
negative swing in intrathoracic pressure and arou-
sals (Fig. 1–3). During recovery following apneas 
or hypopneas, ventilation increases and reoxyge-
nation/hypocapnia ensue. These consequences 
of sleep apnea are qualitatively similar when the 
2 forms of apnea are compared; however, they are 
more pronounced in OSA than CSA (Fig. 3).
A major adverse consequence of apneas/hypo-
pneas is elevated sympathetic nervous system ac-
tivation induced by repetitive arousals and hypoxia/
hypercapnia (Fig. 3) through enhanced peripheral and 
central chemoreceptors [1, 24, 26, 27, 35]. Increased 
sympathetic activity leads to vasoconstriction and 
subsequently to a surge in blood pressure, heart 
rate and left ventricular afterload — changes that 
are particularly unfavorable in patients with HF. As 
a consequence of elevated sympathetic activation 
nocturnal arrhythmias may also occur [11, 13, 29, 34]. 
Most recently [36], it has been shown that in HF 
patients with sleep apnea, current smoking further 
increases the odds ratio for nocturnal arrhythmias 
considerably; nicotine, via activation of the peripher-
al chemoreceptors, a shared pathway with hypoxia, 
increases sympathetic activity and this hand in hand, 
with other consequences of sleep apnea contribute 
to excess nocturnal arrhythmias in HF [39], creat-
ing the substrate for sudden cardiac death, a major 
mode of mortality in these patients. Cessation of 
smoking should have a major impact on prevention 
of sudden cardiac death in HF patients, particularly 
those with sleep apnea as it does in patients with 
coronary artery disease.
Hypoxia and hypercapnia lead to vasoconstric-
tion not only in systemic but also in pulmonary 
circulation resulting in augmented right ventricle 
afterload (Fig. 3). Hypoxia along with reoxygenation 
which occurs with increased ventilation consequent 
to apnea, similar to ischemia-reperfusion, results 
in oxidative stress, infl ammation and eventually 
endothelial dysfunction contributing to progression 
of HF as detailed elsewhere [1, 2]. Activation of 
redox–sensitive genes via transcription factors such 
NFkb are involved in these processes. 
As noted above, the consequences of CSA 
and OSA are qualitatively similar, though there 
are quantitative differences. One such difference 
is the large negative intrathoracic pressure drops 
during upper airway occlusion which defines 
obstructive apnea (Figs. 1, 2). These pressure 
Figure 3. Biological pathways mediating cardiovascular complications of sleep apnea; Ppl — pleural pressure. Mo-
dified from [2]. 
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changes are refl ected in the surrounding of all 
intrathoracic structures and have signifi cant he-
modynamic consequences. Augmented gradient 
between intraventricular pressure and intrathora-
cic (juxtacardiac) pressure, which determines left 
ventricular transmural pressure, causes increased 
ventricular wall tension and oxygen consumption. 
Negative intrathoracic pressure increases venous 
return and right ventricular preload [1, 2] which 
may cause septal deviation impairing left ventri-
cular stroke volume. The negative pressure in the 
lung interstitial compartment promotes pulmonary 
edema (Fig. 3) [1, 2]. The described changes have 
unfavorable impact on left ventricular function and 
may cause or worsen existing HF. 
Not only left ventricular, but also atrial fun-
ction and structure may be affected by repeti-
tive negative shifts in intrathoracic pressure. 
Augmented negative pressure gradient between 
intra-atrial cavites and juxtacardiac space causes 
atrial chamber distension and fi brosis resulting in 
structural atrial remodeling as well as increased 
P-wave duration in ECG recognized as electrical 
atrial remodeling. These pathophysiological chan-
ges along with increased sympathetic activity and 
myocardial hypoxia are believed to be the substrate 
for atrial fi brillation [37].
Regarding negative pressure swings asso-
ciated with CSA, these will be noted during the 
hyperventilation which follows the apnea; the mag-
nitude of the negative pressure changes depend on 
stiffness of the lung and also the depth of inhalation.
Treatment of sleep apnea in HF 
and its impact on cardiovascular 
function and mortality
The various therapeutic approaches for both 
OSA and CSA have been reviewed extensively 
elsewhere [1, 2, 38] and will only be briefl y revie-
wed below.
Obstructive sleep apnea
In OSA, general recommendations include 
lifestyle changes such as exercise, cessation of 
smoking and weight loss when applicable, avo-
idance of alcohol, hypnotics, opioids, phospho-
diesterase inhibitors, and supine position during 
sleep. Pharmacological approaches to treat OSA 
in general have not proven effective [39]. Howe-
ver, fl uid overload should be treated aggressively. 
Phosphodiesterase inhibitors [40] and opioids [41] 
at bed time could worsen sleep apnea and should 
be avoided. Phosphodiesterase inhibitors perhaps 
via vasodilatation and vascular congestion in the 
nasal cavity and upper airway could promote OSA, 
and opioids via central mechanisms could cause 
central and obstructive apneas [41].
Continuous positive airway pressure (CPAP) 
ventilation is the treatment of choice. It provides 
upper airway patency (pneumatic splint) and at 
appropriate airway pressure keeps the upper air-
way open preventing development of obstructive 
apnea and hypopnea. In patients with OSA and 
HF with reduced ejection fraction, 3 randomized 
clinical trials have shown variable [42–44] but sig-
nifi cant increases in LVEF following 1 to 3 month 
therapy with CPAP. In a fourth randomized study 
[45], ejection fraction did not change signifi cantly; 
in this regard, perhaps the most important issue is 
adherence to CPAP [1, 2, 38, 46]. 
There is only one double-blind placebo-con-
trolled (sham CPAP, a CPAP device with minimal 
pressure) trial in HF with presereved ejection 
fraction [47]. In this study of 12 weeks duration, 
effective CPAP therapy resulted in a signifi cant 
increase in E/A ratio and a signifi cant decrease 
in isovolemic relaxation and mitral deceleration 
time [47]. 
In regards to mortality, observational studies 
[4, 5, 48, 49] suggest that HF patients with OSA 
have a shorter survival compared to matched pa-
tients without OSA, and that effective treatment of 
OSA with CPAP [5, 48, 49] improves survival, but 
only in those who remain adherent to CPAP. This 
observation that adherence to CPAP is critical for 
survival, is similar to that noted above for improved 
LVEF. The reason why many HF patients are not 
compliant with CPAP is that they commonly do 
not suffer from excessive day time sleepiness and 
therefore do not see any immediate improvement. 
This is in contrast to garden variety OSA patients 
whose day time sleepiness is eliminated by CPAP 
and therefore they remain CPAP-compliant. Adhe-
rence is the Achilles tendon of CPAP.
In the largest study from US [5] of medicare 
benefi ciaries with newly diagnosed HF, the survival 
of the 258 patients who were diagnosed with sleep 
apnea and were treated for it, was far superior to 
the other 30,065 HF patients who were not tested 
for sleep apnea (Fig. 4).
Central sleep apnea
Multiple studies have shown that CSA is an 
independent predictor of mortality in HF ([3], [6], 
[7]; for reviews see [1], [2]) (Fig. 4). In one of the 
studies with a large number of variables as con-
founders, high AHI, low diastolic blood pressure 
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and right ventricular ejection fraction were the 
3 variables which independently were associated 
with excess mortality [6].
Meanwhile, there are multiple options for 
treatment of CSA in HF. The severity of CSA is 
related to degree of left ventricular dysfunction and 
therefore optimization of medications and resyn-
chronization therapy when applicable are of prima-
ry importance in management before performing 
a sleep study [1, 2]. Optimal medical therapy decre-
ases pulmonary congestion, hyperventilation, and 
circulation time all of which may stabilize breathing 
during sleep. Improvement of CSA during therapy 
with beta-adrenolytics has been demonstrated [50]. 
However, HF is a progressive disorder, and overall 
introduction of beta-blockers has not changed the 
prevalence of sleep apnea in HF (Table 1).
Meanwhile, resynchronization therapy impro-
ves CSA, which is in contrast to OSA. A recent 
meta-analysis [51] of 9 studies (170 patients) 
revealed that in patients with CSA resynchroni-
zation therapy reduced AHI signifi cantly — mean 
reduction in AHI was about 13 events/h whereas 
in OSA it was only 3 events/h. 
Currently, a few options for pharmacotherapy 
of CSA have been studied [52–54]. Nocturnal oxy-
gen therapy eliminates nocturnal oxyhemoglobin 
desaturation, improves VO2 max (see [2] and [52]), 
and also in randomized clinical trials increases 
LVEF and quality of life [55–57].
In small randomized clinical trials, theophyl-
line [53] and acetazolamide [54] have been shown 
effective. However, their safety and long-term be-
nefi ts require large trials. Theophylline stimulates 
breathing by competitive inhibition of adenosine 
from its receptors. However its pro-arrhythmo-
genic properties limit its use in patients with HF. 
Acetazolamide induces mild metabolic acidosis and 
increases the difference between resting PCO2 and 
apnea threshold (PCO2 reserve). 
Several investigators have used CPAP to treat 
central apnea (see [38]). Whereas OSA is initially 
eliminated with overnight CPAP titration only in 
about 50% of patients, CPAP suppresses CSA [58]. 
The mechanisms include decreasing venous return 
and unloading the left ventricle both decreasing 
pulmonary capillary wedge pressure, decreasing 
circulation time, and increasing functional residual 
capacity all of which contribute to stabilization of 
breathing [1, 2, 24]. In addition, in some patients 
with CSA, upper airway closure occurs which is 
reversed by CPAP.
Regarding effects of CPAP on mortality, Brad-
ley et al. [59] carried out a large prospective study 
with the use of CPAP in patients with HF and co-
-morbid CSA (The Canadian Continuous Positive 
Airway Pressure for Patients with Central Sleep 
Apnea and Heart Failure, CANPAP study). Two 
hundred fi fty eight eligible patients were randomi-
zed to either control group with optimal medical 
therapy or to CPAP group with optimal medical 
therapy and CPAP. The average follow up time was 
2 years. The study was terminated prematurely after 
an interim analysis, for several reasons including 
an early excess mortality in the CPAP arm. The 
reason for this excess mortality in the CPAP arm 
has been analyzed in detail elsewhere [60]. The 
major reason was that in almost 50% of the patients 
Figure 4. Kaplan-Maier survival curves, adjusted by age, gender, and Charlson Comorbidity Index, 2004–2005. Sur-
vival of heart failure (HF) patients diagnosed and treated for sleep apnea compared with the remaining patients who 
were not tested for sleep apnea. Modified from [5].
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CSA was not suppressed by CPAP (these patients 
are considered CPAP non responders). Indeed, in 
a post hoc analysis, longer survival without heart 
transplant was reported in patients in whom CPAP 
effectively suppressed CSA (drop in AHI < 15/h, 
mean = 6/h from a baseline of about 40/h) in com-
parison to the control group [7]. 
For CPAP nonresponders, adaptive servoven-
tilator (ASV) devices are the treatment of choice. 
The operation algorithm of these devices is quite 
unique and different from CPAP or bi-level devices 
[61]. There are 3 specifi c features: fi rst, these de-
vices stabilize the upper airway by applying a fi xed 
(old generations) or variable expiratory positive 
airway pressure (automatic, like autoCPAP, new 
generations) to eliminate obstructive disordered 
breathing. Second, they act as a ventilator and de-
liver a mandated breath, if spontaneous breathing 
ceases for just few seconds. Third, they counter-
balance ventilatory instability by modulating the 
degree of inspiratory pressure support (defi ned 
as inspiratory pressure minus expiratory pres-
sure). In this regard, based on unique algorithms, 
the inspiratory positive airway pressure, and 
therefore the inspiratory support, varies in an 
anti-cyclic manner opposite to the prevailing fl ow 
or minute ventilation of the patient. Thus, tidal 
volume increases during hypoventilation and de-
creases during hyperventilation. This component 
of ventilation that is anti-cyclic to the periodicity 
of the patient’s own breathing, acts to dampen the 
oscillations in the ventilatory drive that underlie 
periodic breathing.  
Teschler et al. [62] are credited with the fi rst 
ASV study showing that in a 5 arm overnight study, 
ASV was more effective than oxygen, CPAP and 
bi-level therapy. In a meta-analysis of multiple 
studies using ASV as a contrast group (O2, CPAP, 
or continued medical therapy), will show that 
ASV improves AHI and LVEF signifi cantly [63]. 
Two observational long-term studies [8, 10] have 
demonstrated improved survival in those who used 
the ASV device compared to those who refused. 
Currently, 2 large prospective trials are ongoing 
— SERVE-HF and ADVENT-HF. Patients with 
HF and coexisting sleep apnea (in the fi rst study 
CSA, in the second CSA or OSA) are randomized 
into 2 groups: the fi rst group on optimal medical 
therapy for HF or the second group treated ad-
ditionally with ASV. The results of these studies 
should answer the question whether ventilation by 
means of ASV infl uences long term prognosis and 
frequency of hospital re-admissions.
Despite proven beneficial effects of CPAP 
and also ASV therapy, a number of patients cannot 
tolerate mask/positive pressure device therapy; as 
noted before, most HF patients with sleep apnea 
do not see immediate improvement with the use of 
these devices. We believe this is the major factor 
infl uencing non-adherence. Therefore new thera-
peutic methods are currently a subject of research. 
An important advancement is transvenous phrenic 
nerve stimulation, which is easily placed by an 
electrophysiologist. This acts like a pacemaker 
stimulating the phrenic nerve during sleep. In 
a preliminary study [64] a temporary transvenous 
lead was placed in either the right brachiocephalic 
or left pericardiophrenic vein in 13 patients with 
HF and confi rmed CSA. During PSG on therapy 
night, when phrenic nerve stimulation was applied, 
a signifi cant decrease in AHI and central apnea in-
dex was observed when compared to control night 
without phrenic nerve stimulation. Simultaneously, 
arousal index related to periodic breathing signifi -
cantly decreased. This novel method is important 
for a variety of reasons including the ease of use 
by the patient which should improve adherence, 
an important drawback of mask/positive airway 
therapy. Long-term studies with phrenic nerve sti-
mulation are pending. Finally we note that cardiac 
transplantation virtually eliminates CSA indicating 
that CSA is the consequence of HF [65]. Unfortuna-
tely, however, a large number of cardiac-transplant 
recipients gain weight and develop OSA. 
Conclusions
Despite recent advances in HF management, 
quality of life, hospital readmissions and mortality 
remain unacceptably high. Therefore, an increasing 
focus on treating co-morbidities which could change 
such grim prognosis is clinically relevant. SDB is 
reported to be among most common co-morbidities 
affecting HF patients. It occurs in at least half of 
HF population and is associated with more severe 
HF symptoms, lower ejection fraction and higher 
prevalence of arrhythmia. SDB has also been proven 
to be an independent risk factor of poor outcome. 
There are documented treatment options based on 
positive airway pressure ventilation, which suc-
cessfully reduce number of apnea episodes, but also 
improve left ventricular systolic function, exercise 
tolerance and possibly long term prognosis. Due 
to low recognition of SBD it seems necessary to 
introduce routine investigations in patients with HF, 
especially with new promising treatment methods 
such as phrenic nerve stimulation. 
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